• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    H.C. Wainwright resumed coverage on RAPT Therapeutics with a new price target

    5/22/25 8:27:06 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RAPT alert in real time by email
    H.C. Wainwright resumed coverage of RAPT Therapeutics with a rating of Buy and set a new price target of $6.00
    Get the next $RAPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RAPT

    DatePrice TargetRatingAnalyst
    5/22/2025$6.00Buy
    H.C. Wainwright
    12/26/2024$10.00Neutral → Buy
    H.C. Wainwright
    11/13/2024$7.00 → $2.00Buy → Hold
    Stifel
    11/11/2024$8.00 → $2.00Overweight → Neutral
    Piper Sandler
    11/11/2024Neutral → Underweight
    JP Morgan
    5/14/2024Outperform → Peer Perform
    Wolfe Research
    5/10/2024Buy → Neutral
    Guggenheim
    5/10/2024$13.00 → $4.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $RAPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company's lead product candidate RPT904, is a novel, half-life extended monoclonal antibod

      6/23/25 8:00:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

      SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) (the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Global Market under the symbol "RAPT" with the new CUSIP number 75382E 208. The Company's common stock will begin trading on a rever

      6/13/25 9:00:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics to Participate in Upcoming Investor Conferences

      SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in June: Goldman Sachs 46th Annual Global Healthcare Conference – Fireside chat on Tuesday, June 10, 2025 at 9:20 a.m. ETUBS Spring Biotech Conference – Investor one-on-one meetings on Tuesday, June 24, 2025 To access the live webcast or subsequent archived recording of the Goldman Sa

      6/4/25 4:05:00 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPT
    SEC Filings

    See more
    • RAPT Therapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K - RAPT Therapeutics, Inc. (0001673772) (Filer)

      6/23/25 8:10:26 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by RAPT Therapeutics Inc.

      S-8 - RAPT Therapeutics, Inc. (0001673772) (Filer)

      6/20/25 8:11:22 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - RAPT Therapeutics, Inc. (0001673772) (Filer)

      6/17/25 4:10:26 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Braunstein Scott

      4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

      6/24/25 4:25:28 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Braunstein Scott

      3 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

      6/24/25 4:23:33 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF MEDICAL OFFICER Ho William

      4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

      6/24/25 4:21:48 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on RAPT Therapeutics with a new price target

      H.C. Wainwright resumed coverage of RAPT Therapeutics with a rating of Buy and set a new price target of $6.00

      5/22/25 8:27:06 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded RAPT Therapeutics from Neutral to Buy and set a new price target of $10.00

      12/26/24 7:14:12 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded RAPT Therapeutics from Buy to Hold and set a new price target of $2.00 from $7.00 previously

      11/13/24 8:21:31 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

      SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

      11/14/24 1:22:39 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

      SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

      11/14/24 9:39:56 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

      SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

      11/12/24 4:59:18 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care